PMID- 38027465
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231201
IS  - 2471-2531 (Electronic)
IS  - 2471-2531 (Linking)
VI  - 8
IP  - 6
DP  - 2023 Dec
TI  - Effects of pharmacogenetic profiles on pediatric pain relief and adverse events 
      with ibuprofen and oxycodone.
PG  - e1113
LID - 10.1097/PR9.0000000000001113 [doi]
LID - e1113
AB  - INTRODUCTION: Individual genetic variation may influence clinical effects for 
      pain medications. Effects of CYP2C9, CYP3A4, and CYP2D6 polymorphisms on clinical 
      effectiveness and safety for ibuprofen and oxycodone were studied. OBJECTIVE: 
      Primary objectives were to AU2 evaluate if allelic variations would affect 
      clinical effectiveness and adverse events (AEs) occurrence. METHODS: This 
      pragmatic prospective, observational cohort included children aged 4 to 16 years 
      who were seen in a pediatric emergency department with an acute fracture and 
      prescribed ibuprofen or oxycodone for at-home pain management. Saliva samples 
      were obtained for genotyping of allelic variants, and daily telephone follow-up 
      was conducted for 3 days. Pain was measured using the Faces Pain Scale-Revised. 
      RESULTS: We included 210 children (n = 140 ibuprofen and n = 70 oxycodone); mean 
      age was 11.1 (+/-SD 3.5) years, 33.8% were female. Median pain reduction on day 1 
      was similar between groups [ibuprofen 4 (IQR 2,4) and oxycodone 4 (IQR 2,6), P = 
      0.69]. Over the 3 days, the oxycodone group experienced more AE than the 
      ibuprofen group (78.3% vs 53.2%, P < 0.001). Those with a CYP2C9*2 reduced 
      function allele experienced less adverse events with ibuprofen compared with 
      those with a normal functioning allele CYP2C9*1 (P = 0.003). Neither CYP3A4 
      variants nor CYP2D6 phenotype classification affected clinical effect or AE. 
      CONCLUSION: Although pain relief was similar, children receiving oxycodone 
      experienced more AE, overall, than those receiving ibuprofen. For children 
      receiving ibuprofen or oxycodone, pain relief was not affected by genetic 
      variations in CYP2C9 or CYP3A4/CYP2D6, respectively. For children receiving 
      ibuprofen, the presence of CYP2C9*2 was associated with less adverse events.
CI  - Copyright (c) 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on 
      behalf of The International Association for the Study of Pain.
FAU - Ali, Samina
AU  - Ali S
AD  - Department of Pediatrics, Faculty of Medicine & Dentistry and Women & Children's 
      Health Research Institute (WCHRI), University of Alberta, Edmonton, AB, Canada.
FAU - Yukseloglu, Aran
AU  - Yukseloglu A
AD  - Department of Pediatrics, Faculty of Medicine & Dentistry and Women & Children's 
      Health Research Institute (WCHRI), University of Alberta, Edmonton, AB, Canada.
FAU - Ross, Colin J
AU  - Ross CJ
AD  - Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, 
      BC, Canada.
FAU - Rosychuk, Rhonda J
AU  - Rosychuk RJ
AD  - Department of Pediatrics, Faculty of Medicine & Dentistry and Women & Children's 
      Health Research Institute (WCHRI), University of Alberta, Edmonton, AB, Canada.
FAU - Drendel, Amy L
AU  - Drendel AL
AD  - Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, USA.
FAU - Manaloor, Robin
AU  - Manaloor R
AD  - Department of Anaesthesiology, College of Medicine, University of Saskatchewan, 
      Saskatoon, SK, Canada.
FAU - Johnson, David W
AU  - Johnson DW
AD  - Department of Pediatrics, Alberta Children's Hospital, University of Calgary, 
      Calgary, AB, Canada.
FAU - Le May, Sylvie
AU  - Le May S
AD  - Faculty of Nursing, Universite de Montreal, CHU Sainte-Justine Research Centre, 
      Montreal, QC, Canada.
FAU - Carleton, Bruce
AU  - Carleton B
AD  - Division of Translational Therapeutics, Department of Pediatrics, Faculty of 
      Medicine, University of British Columbia, Vancouver, BC, Canada.
LA  - eng
PT  - Journal Article
DEP - 20231017
PL  - United States
TA  - Pain Rep
JT  - Pain reports
JID - 101683899
PMC - PMC10659733
OTO - NOTNLM
OT  - Analgesia
OT  - Children
OT  - Opioids
OT  - Pharmacogenomics
OT  - Side effects
COIS- The authors have no conflict of interest to declare.Sponsorships or competing 
      interests that may be relevant to content are disclosed at the end of this 
      article.
EDAT- 2023/11/29 18:42
MHDA- 2023/11/29 18:43
PMCR- 2023/10/17
CRDT- 2023/11/29 17:05
PHST- 2022/12/16 00:00 [received]
PHST- 2023/07/27 00:00 [revised]
PHST- 2023/08/10 00:00 [accepted]
PHST- 2023/11/29 18:43 [medline]
PHST- 2023/11/29 18:42 [pubmed]
PHST- 2023/11/29 17:05 [entrez]
PHST- 2023/10/17 00:00 [pmc-release]
AID - PAINREPORTS-D-22-0155 [pii]
AID - 10.1097/PR9.0000000000001113 [doi]
PST - epublish
SO  - Pain Rep. 2023 Oct 17;8(6):e1113. doi: 10.1097/PR9.0000000000001113. eCollection 
      2023 Dec.